Red Nucleus acquires Bridge Medical Consulting
Red Nucleus, a Yardley, PA-based life sciences consulting firm, has acquired Bridge Medical Consulting, a London-based health economics and outcomes research (HEOR) consulting firm.
Founded in 2011, Bridge provides expertise in evidence synthesis, integrated evidence planning, population insights, health economic modeling, and statistics to pharmaceutical and biotech clients across Europe and the United States.
The firm has a team of approximately 60 experienced physicians, epidemiologists, outcomes researchers, statisticians, AI scientists, and data visualization specialists across offices in London and New Delhi.
Red Nucleus’ acquisition of Bridge will strengthen its ability to help biopharma clients demonstrate the clinal and economic value of therapies in a complex regulatory and reimbursement environment. Evolving global requirements include demand for real-world evidence, joint clinical assessments in Europe, and more rigorous value-based decision-making by health authorities.
“With payers and regulators placing unprecedented scrutiny on drug pricing and value, HEOR has become mission-critical for life sciences companies,” said Mike Menta, CEO of Red Nucleus. “This acquisition enhances our ability to support clients across value, evidence, and market access.”
Red Nucleus will add the Bridge team to its existing global HEOR practice.
“We share a commitment to scientific excellence and to thoughtfully applying AI and related technologies to enhance rigor and efficiency, while keeping expert judgment at the center of our work,” said Paul Gandhi, founder and CEO of Bridge Medical Consulting. “The combined platform brings together complementary expertise that will benefit customers of both companies.”
Red Nucleus was founded in 1991 and has 800 people across 10 offices in North America, EMEA, and Asia-Pacific. The firm services in research and development, medical affairs, market access, commercial, and learning and development to the life sciences industry.
